Mutational landscape of gastric adenocarcinoma in Chinese: Implications for prognosis and therapy

Proceedings of the National Academy of Sciences of the United States of America

Volumn 112, Issue 4, 2015, Pages 1107-1112

  Chen, Kexin ^a   Yang, Da ^b,c   Li, Xiangchun ^d,e   Sun, Baocun ^a   Song, Fengju ^a   Cao, Wenfeng ^a   Brat, Daniel J ^f   Gao, Zhibo ^d   Li, Haixin ^a   Liang, Han ^a   Zhao, Yanrui ^a   Zheng, Hong ^a   Li, Miao ^d   Buckner, Jan ^g   Patterson, Scott D ^h   Ye, Xiang ⁱ   Reinhard, Christoph ⁱ   Bhathena, Anahita ^j   Joshi, Deepa ^k   Mischel, Paul S ^l   Croce, Carlo M ^m   Wang, Yi Michael ⁿ   Raghavakaimal, Sreekumar ⁿ   Li, Hui ^a   Lu, Xin ^j   Pan, Yang ^h   Chang, Han ^k   Ba, Sujuan ^n,o   Luo, Longhai ^d,p   Cavenee, Webster K ^l   Zhang, Wei ^b   Hao, Xishan ^a   more..

^a TIANJIN MEDICAL UNIVERSITY   (China)

^b UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^c UNIVERSITY OF PITTSBURGH   (United States)

^d BGI SHENZHEN   (China)

^e CHINESE UNIVERSITY OF HONG KONG   (Hong Kong)

^f EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^g MAYO CLINIC   (United States)

^h AMGEN INC   (United States)

ⁱ ELI LILLY AND COMPANY   (United States)

^j ABBVIE INC   (United States)

^k BRISTOL MYERS SQUIBB   (United States)

^l UNIVERSITY OF CALIFORNIA   (United States)

^m OHIO STATE UNIVERSITY   (United States)

ⁿ Center for Metastasis Research   (United States)

^o Asian Fund for Cancer Research   (China)

^p UNIVERSITY OF COPENHAGEN   (Denmark)

more..

Author keywords

BRCA2; Clonality; ERBB; Exome sequencing; Mutation

Indexed keywords

AT RICH INTERACTIVE DOMAIN 1A; BRCA2 PROTEIN; MEMBRANE PROTEIN; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN P53; UNCLASSIFIED DRUG; WNT PROTEIN; TUMOR PROTEIN;

AGE DISTRIBUTION; ARTICLE; CANCER PROGNOSIS; CANCER SURVIVAL; CANCER THERAPY; CHINESE; CLONAL EVOLUTION; CLONAL VARIATION; COHORT ANALYSIS; DISEASE ASSOCIATION; EXOME; GENE MUTATION; GENE SEQUENCE; GENETIC DISORDER; HISTOLOGY; HUMAN; HUMAN TISSUE; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; METASTASIS; PHYLOGENETIC TREE; PRIMARY TUMOR; PRIORITY JOURNAL; PROTO ONCOGENE; RECOMBINATION REPAIR; STOMACH ADENOCARCINOMA; VIRUS ONCOGENE; ADENOCARCINOMA; AGE; ASIAN CONTINENTAL ANCESTRY GROUP; CASE CONTROL STUDY; CHINA; DISEASE FREE SURVIVAL; EPIDEMIOLOGY; FEMALE; GENETIC ASSOCIATION; GENETICS; HOMOLOGOUS RECOMBINATION; MALE; MORTALITY; MUTATION; NUCLEIC ACID DATABASE; NUCLEOTIDE SEQUENCE; STOMACH NEOPLASMS; SURVIVAL RATE;

AVES;

ADENOCARCINOMA; AGE FACTORS; ASIAN CONTINENTAL ANCESTRY GROUP; CASE-CONTROL STUDIES; CHINA; DATABASES, NUCLEIC ACID; DISEASE-FREE SURVIVAL; DNA MUTATIONAL ANALYSIS; FEMALE; GENOME-WIDE ASSOCIATION STUDY; HOMOLOGOUS RECOMBINATION; HUMANS; MALE; MUTATION; NEOPLASM PROTEINS; STOMACH NEOPLASMS; SURVIVAL RATE;

EID: 84921747414     PISSN: 00278424     EISSN: 10916490     Source Type: Journal    
DOI: 10.1073/pnas.1422640112     Document Type: Article

References (24)

1. Ferlay J, et al. (2010) Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer 127(12):2893-2917.
2. Uemura N, et al. (2001) Helicobacter pylori infection and the development of gastric cancer. N Engl J Med 345(11):784-789.
3. Murphy G, Pfeiffer R, Camargo MC, Rabkin CS (2009) Meta-analysis shows that prevalence of Epstein-Barr virus-positive gastric cancer differs based on sex and anatomic location. Gastroenterology 137(3):824-833.
4. Shah MA, Ajani JA (2010) Gastric cancer - An enigmatic and heterogeneous disease. JAMA 303(17):1753-1754.
5. Catalano V, et al. (2009) Gastric cancer. Crit Rev Oncol Hematol 71(2):127-164.
6. Chen W, et al. (2013) The incidences and mortalities of major cancers in China, 2009. Chin J Cancer 32(3):106-112.
7. Kim B, et al. (2003) Expression profiling and subtype-specific expression of stomach cancer. Cancer Res 63(23):8248-8255.
8. Song F, et al. (2014) Integrated microRNA network analyses identify a poor-prognosis subtype of gastric cancer characterized by the miR-200 family. Clin Cancer Res 20(4):878-889.
9. Wang K, et al. (2011) Exome sequencing identifies frequent mutation of ARID1A in molecular subtypes of gastric cancer. Nat Genet 43(12):1219-1223.
10. Bass AJ, et al.; Cancer Genome Atlas Research Network (2014) Comprehensive molecular characterization of gastric adenocarcinoma. Nature 513(7517):202-209.
11. Wang K, et al. (2014) Whole-genome sequencing and comprehensive molecular profiling identify new driver mutations in gastric cancer. Nat Genet 46(6):573-582.
12. Kakiuchi M, et al. (2014) Recurrent gain-of-function mutations of RHOA in diffusetype gastric carcinoma. Nat Genet 46(6):583-587.
13. Cibulskis K, et al. (2013) Sensitive detection of somatic point mutations in impure and heterogeneous cancer samples. Nat Biotechnol 31(3):213-219.
14. Koboldt DC, et al. (2012) VarScan 2: Somatic mutation and copy number alteration discovery in cancer by exome sequencing. Genome Res 22(3):568-576.
15. Miller CA, et al. (2014) SciClone: Inferring clonal architecture and tracking the spatial and temporal patterns of tumor evolution. PLOS Comput Biol 10(8): e1003665.
16. Landau DA, et al. (2013) Evolution and impact of subclonal mutations in chronic lymphocytic leukemia. Cell 152(4):714-726.
17. Alexandrov LB, et al.; Australian Pancreatic Cancer Genome Initiative; ICGC Breast Cancer Consortium; ICGC MMML-Seq Consortium; ICGC PedBrain (2013) Signatures of mutational processes in human cancer. Nature 500(7463):415-421.
18. Lawrence MS, et al. (2013) Mutational heterogeneity in cancer and the search for new cancer-associated genes. Nature 499(7457):214-218.
19. Griffith M, et al. (2013) DGIdb: Mining the druggable genome. Nat Methods 10(12):1209-1210.
20. Makishima H, et al. (2013) Somatic SETBP1 mutations in myeloid malignancies. Nat Genet 45(8):942-946.
21. Prickett TD, et al. (2009) Analysis of the tyrosine kinome in melanoma reveals recurrent mutations in ERBB4. Nat Genet 41(10):1127-1132.
22. Wilson TR, Lee DY, Berry L, Shames DS, Settleman J (2011) Neuregulin-1-mediated autocrine signaling underlies sensitivity to HER2 kinase inhibitors in a subset of human cancers. Cancer Cell 20(2):158-172.
23. Friedenson B (2005) BRCA1 and BRCA2 pathways and the risk of cancers other than breast or ovarian. MedGenMed 7(2):60.
24. Yang D, et al. (2011) Association of BRCA1 and BRCA2 mutations with survival, chemotherapy sensitivity, and gene mutator phenotype in patients with ovarian cancer. JAMA 306(14):1557-1565.